How we approach malignant infantile osteopetrosis.
hematopoietic stem cell transplantation
malignant infantile osteopetrosis
osteoclast
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
17
08
2020
revised:
22
11
2020
accepted:
23
11
2020
pubmed:
15
12
2020
medline:
3
8
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder characterized by excessive bone overgrowth due to a defect in bone marrow resorption by osteoclasts. In most cases, hematopoietic stem cell transplantation (HSCT) may correct bone metabolism but the rapidly progressing nature of this condition necessitates early diagnosis and prompt treatment to minimize irreversible cranial nerve damage. The management of patients with MIOP presents many unique challenges. In this review, the clinical management of patients with MIOP is discussed, including diagnosis, preparation for HSCT and special transplant considerations, management of unique HSCT complications, and long-term follow-up.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28841Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351:2839-2849.
Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5.
Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9:522-536.
Coccia PF, Krivit W, Cervenka J, et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med. 1980;302:701-708.
Orchard PJ, Fasth AL, Le Rademacher J, et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015;126:270-276.
Bliznetz EA, Tverskaya SM, Zinchenko RA, et al. Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect. Eur J Hum Genet. 2009;17:664-672.
Anderson SL, Jalas C, Fedick A, et al. A founder mutation in the TCIRG1 gene causes osteopetrosis in the Ashkenazi Jewish population. Clin Genet. 2015;88:74-79.
Zlotogora J. Autosomal recessive diseases among Palestinian Arabs. J Med Genet. 1997;34:765-766.
Siatkowski RM, Vilar NF, Sternau L, Coin CG. Blindness from bad bones. Surv Ophthalmol. 1999;43:487-490.
Chen C-J, Lee M-Y, Hsu M-L, Lien S-H, Cheng S-N. Malignant infantile osteopetrosis initially presenting with neonatal hypocalcemia: case report. Ann Hematol. 2003;82:64-67.
Engiz O, Kara S, Bagrul D, et al. Infantile malignant osteopetrosis: a rare cause of neonatal hypocalcemia. J Pediatr Endocrinol Metab. 2012;25:1205-1207.
Nilesh K. Extensive maxillary osteomyelitis following tooth extraction in a patient with osteopetrosis. BMJ Case Rep. 2020:13.
de Machado CV, da Rocha MCBS, Telles PD, da S. Infantile osteopetrosis associated with osteomyelitis. BMJ Case Rep. 2015.
Strauss A, Furlan I, Steinmann S, et al. Unmistakable morphology? Infantile malignant osteopetrosis resembling juvenile myelomonocytic leukemia in infants. J Pediatr. 2015;167:486-488.
Hoyoux C, Dresse MF, Forget P, et al. Osteopetrosis mimicking juvenile myelomonocytic leukemia. Pediatr Int. 2014;56:779-782.
Capo V, Penna S, Merelli I, et al. Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis. Haematologica. 2020. doi: 10.3324/haematol.2019.238261
Cummings TJ, Proia AD. Optic nerve compression in infantile malignant autosomal recessive osteopetrosis. J Pediatr Ophthalmol Strabismus. 2004;41:241-244.
Simanovsky N, Rozovsky K, Hiller N, Weintraub M, Stepensky P. Extending the spectrum of radiological findings in patients with severe osteopetrosis and different genetic backgrounds. Pediatr Blood Cancer. 2016;63:1222-1226.
Pangrazio A, Fasth A, Sbardellati A, et al. SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity. J bone Miner Res Off J Am Soc Bone Miner Res. 2013;28:1041-1049.
Palagano E, Menale C, Sobacchi C, Villa A. Genetics of osteopetrosis. Curr Osteoporos Rep. 2018;16:13-25.
Penna S, Capo V, Palagano E, Sobacchi C, Villa A. One disease, many genes: implications for the treatment of osteopetroses. Front Endocrinol (Lausanne). 2019;10:85.
Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med. 2018;379:1353-1362.
Shamriz O, Shaag A, Yaacov B, et al. The use of whole exome sequencing for the diagnosis of autosomal recessive malignant infantile osteopetrosis. Clin Genet. 2017;92:80-85.
Palagano E, Blair HC, Pangrazio A, et al. Buried in the middle but guilty: intronic mutations in the TCIRG1 gene cause human autosomal recessive osteopetrosis. J bone Miner Res Off J Am Soc Bone Miner Res. 2015;30:1814-1821.
Bénichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone. 2000;26:87-93.
Wu CC, Econs MJ, DiMeglio LA, et al. Diagnosis and management of osteopetrosis: consensus guidelines from the Osteopetrosis Working Group. J Clin Endocrinol Metab. 2017;102:3111-3123.
Stepensky P, Grisariu S, Avni B, et al. Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. Blood Adv. 2019;3:862-868.
Hashemi Taheri AP, Radmard AR, Kooraki S, et al. Radiologic resolution of malignant infantile osteopetrosis skeletal changes following hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62:1645-1649.
Curé JK, Key LL, Goltra DD, VanTassel P. Cranial MR imaging of osteopetrosis. AJNR Am J Neuroradiol. 2000;21:1110-1115.
Stella I, Vinchon M, Guerreschi P, De Berranger E, Bouacha I. Case update on cranial osteopetrosis: which is the role of the neurosurgeon? Childs Nerv Syst. 2017;33:2181-2186.
Abinun M, Newson T, Rowe PW, Flood TJ, Cant AJ. Importance of neurological assessment before bone marrow transplantation for osteopetrosis. Arch Dis Child. 1999;80:273-274.
Sobacchi C, Villa A, Schulz A, Kornak U. In: Adam MP, Ardinger HH, Pagon RA, et al. CLCN7-Related Osteopetrosis. eds. GeneReviews® [Internet]. Seattle, WA: University of Washington; 2016.
Steward CG, Pellier I, Mahajan A, et al. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol. 2004;124:63-71.
Detailleur V, Vansteenkiste G, Renard M, Verdonck A. Dental care approach in patients with osteopetrosis. Eur Arch Paediatr Dent Off J Eur Acad Paediatr Dent. 2016;17:435-443.
Thompson DA, Kriss A, Taylor D, et al. Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis. Neuropediatrics. 1998;29:137-144.
Chiesa R, Ruggeri A, Paviglianiti A, et al. Outcomes after unrelated umbilical cord blood transplantation for children with osteopetrosis. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2016;22:1997-2002.
Schulz AS, Classen CF, Mihatsch WA, et al. HLA-haploidentical blood progenitor cell transplantation in osteopetrosis. Blood. 2002;99:3458-3460.
Pronk CJ, Turkiewicz D, Vult von Steyern K, Ehinger M, Dykes J, Toporski J. Transplantation of haploidentical tcrab-depleted hematopoietic cells allows for optimal timing and sustained correction of the metabolic defect in children with infantile osteopetrosis. J Bone Miner Res. 2017;32:82-85.
Neven B, Diana JS, Castelle M, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019;25:1363-1373.
Even-Or E, NaserEddin A, Dinur-Schejter Y, Shadur B, Zaidman I, Stepensky P. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other non-malignant diseases. Bone Marrow Transpl. 2020. in press.
Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatr Blood Cancer. 2018;65:e27010.
Gerritsen EJ, Vossen JM, Fasth A, et al. Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr. 1994;125:896-902.
Natsheh J, Drozdinsky G, Simanovsky N, et al. Improved outcomes of hematopoietic stem cell transplantation in patients with infantile malignant osteopetrosis using fludarabine-based conditioning. Pediatr Blood Cancer. 2016;63:535-540.
Schulz AS, Moshous D, Steward CG, Villa A, Sobacchi COsteopetrosis: consensus guidelines for diagnosis, therapy and follow-up Version 3. 2015.. https://esid.org/content/download/15294/420706/file/00_OP_Guidelines_V3.pdf.
Wynn R, Schulz A, Inborn errors of metabolism and osteopetrosis. In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. Carreras E, Dufour C, Mohty M, Kröger N 7th edition. Cham (CH): Springer; 2019. Chapter 90. 2019:671-676
Corbacioglu S, Hönig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006;38:547-553.
Even-Or E, Altman Kohl S, Zaidman I, Stepensky P, Molho-Pessach V. Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Transplant. 2020;24:e13626.
Kasow KA, Stocks RMS, Kaste SC, et al. Airway evaluation and management in 7 children with malignant infantile osteopetrosis before hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2008;30:225-229.
Stepensky P, Schulz AS, Lahr G, et al. Successful second haploidentical SCT in osteopetrosis. Bone Marrow Transplant. 2011;46:1021-1022.
Martinez C, Polgreen LE, DeFor TE, et al. Characterization and management of hypercalcemia following transplantation for osteopetrosis. Bone Marrow Transplant. 2010;45:939-944.
Inzerillo AM, Zaidi M, Huang CLH. Calcitonin: physiological actions and clinical applications. J Pediatr Endocrinol Metab. 2004;17:931-940.
Waterhouse KM, Auron A, Srivastava T, Haney C, Alon US. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol. 2007;22:282-287.
Shroff R, Beringer O, Rao K, Hofbauer LC, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis. N Engl J Med. 2012;367:1766-1767.
Stikvoort A, Sundin M, Uzunel M, et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant. PLoS One. 2016;11:e0154737.
Löfvall H, Rothe M, Schambach A, Henriksen K, Richter J, Moscatelli I. Hematopoietic stem cell-targeted neonatal gene therapy with a clinically applicable lentiviral vector corrects osteopetrosis in oc/oc mice. Hum Gene Ther. 2019;30:1395-1404.
Badv RS, Dehghani SS, Behfar M, Ahadi B, Tabasi A, Hamidieh AA. Impact of hematopoietic stem cell transplant on VEP and ABR values of the patients with malignant infantile osteopetrosis. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2018;22:718-724.
Mazzolari E, Forino C, Razza A, Porta F, Villa A, Notarangelo LD. A single-center experience in 20 patients with infantile malignant osteopetrosis. Am J Hematol. 2009;84:473-479.
Shapiro G, Fishleder J, Stepensky P, Simanovsky N, Goldman V, Lamdan R. Skeletal changes after hematopoietic stem cell transplantation in osteopetrosis. J bone Miner Res Off J Am Soc Bone Miner Res. 2020;35:1645-1651.
Driessen GJA, Gerritsen EJA, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant. 2003;32:657-663.
Singer S, Davidovitch N, Abu Fraiha Y, Abu Freha N. Consanguinity and genetic diseases among the Bedouin population in the Negev. J Community Genet. 2020;11:13-19.